Moving the Needle on Atherosclerotic Cardiovascular Disease and Heart Failure with Influenza Vaccination | springermedizin.de

Springer Medizin

nach oben

Current Atherosclerosis Reports

Erschienen in:

01.12.2021 | Cardiovascular Disease and Stroke (J. A. Underberg and J. Newman, Section Editors)

Moving the Needle on Atherosclerotic Cardiovascular Disease and Heart Failure with Influenza Vaccination

verfasst von: Bahar Behrouzi, Jacob A. Udell

Erschienen in: Current Atherosclerosis Reports | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The interplay between viral respiratory infections and cardiovascular disease has been most comprehensively researched using seasonal and pandemic influenza viruses as case studies. Here, we summarize the latest international observational research and clinical trials that examined the association between influenza, influenza vaccines, and cardiovascular disease, while contextualizing their findings within those of landmark studies.

Recent Findings

Most recent observational literature found that one in eight adults hospitalized with laboratory-confirmed influenza infection experienced an acute cardiovascular event. The latest meta-analysis of the cardioprotective effects of influenza vaccine found a 25% reduced risk of all-cause death. There are four large cardiovascular outcome trials assessing the cardioprotective effects of different influenza vaccine strategies. Among these, the INVESTED study showed there is no significant difference between the high-dose trivalent and standard-dose quadrivalent influenza vaccines in reducing all-cause mortality or cardiopulmonary hospitalizations in a high-risk patient group with pre-existing cardiovascular disease.

Summary

Persons with cardiovascular disease represent a high priority group for viral vaccines; hence, using robust evidence to increase vaccine confidence among patients and practitioners is integral as we prepare for a possible influenza resurgence in the coming years.

Anzeige

1.

Ahmad FB, Anderson RN. The leading causes of death in the US for 2020. JAMA. 2021. https://doi.org/10.1001/jama.2021.5469.CrossRefPubMed

2.

Garber AM. Learning from excess pandemic deaths. JAMA. 2021;325:1729.

3.

Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020;371:m3731.

4.

Udell JA, Behrouzi B, Sivaswamy A, et al. Clinical risk, sociodemographic factors, and SARS-CoV-2 infection over time in Ontario, Canada. medRxiv Prepr. 2021. https://doi.org/10.1101/2021.04.28.21256.CrossRef

5.

Walker TA, Waite B, Thompson MG, et al. Risk of severe influenza among adults with chronic medical conditions. J Infect Dis. 2020;221:183–90.PubMed

6.

Cohen R, Babushkin F, Geller K, Finn T. Characteristics of hospitalized adult patients with laboratory documented Influenza A, B and respiratory syncytial virus – a single center retrospective observational study. PLoS One. 2019;14:e0214517.PubMedPubMedCentral

7.

•• Chow EJ, Rolfes MA, O’Halloran A, et al. Acute cardiovascular events associated with influenza in hospitalized adults. Ann Intern Med. 2020;173:605–13 This is a cross-sectional study of FluSurv-NET to determine risk factors for acute HF and acute ischemic heart disease in adults with a hospitalization associated with laboratory-confirmed influenza.PubMedPubMedCentral

8.

Prasad N, Walker TA, Waite B, et al. Respiratory syncytial virus–associated hospitalizations among adults with chronic medical conditions. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa730.CrossRefPubMedPubMedCentral

9.

Chuaychoo B, Ngamwongwan S, Kaewnaphan B, Athipanyasilp N, Horthongkham N, Kantakamalakul W, Muangman N. Clinical manifestations and outcomes of respiratory syncytial virus infection in adult hospitalized patients. J Clin Virol. 2019;117:103–8.PubMedPubMedCentral

10.

Ivey KS, Edwards KM, Talbot HK. Respiratory syncytial virus and associations with cardiovascular disease in adults. J Am Coll Cardiol. 2018;71:1574–83.PubMed

11.

Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system. JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.1286.CrossRefPubMed

12.

• Behrouzi B, Araujo Campoverde MV, Liang K, et al. Influenza vaccination to reduce cardiovascular morbidity and mortality in patients with COVID-19. J Am Coll Cardiol. 2020;76:1777–94 This narrative review provides a thorough summary of landmark studies assessing the association between influenza and CVD, as well as the cardioprotective effects of influenza vaccine.PubMedPubMedCentral

13.

Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378:345–53.PubMed

14.

Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010;10:83–92.PubMed

15.

Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis. 2009;9:601–10.PubMed

16.

Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611–8.PubMed

17.

Collins S. Excess mortality from causes other than influenza and pneumonia during influenza epidemic. Public Health Rep. 1932;47:2159–79.

18.

Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179.PubMed

19.

Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. J Am Med Assoc. 2004;292:1333.

20.

Centers for Diseases Control and Prevention (CDC). Flu & people with heart disease or history of stroke. In: Who is High Risk Flu Complicat. 2021. https://www.cdc.gov/flu/highrisk/heartdisease.htm. Accessed 29 Mar 2021.

21.

Centers for Diseases Control and Prevention (CDC). Estimated influenza illnesses, medical visits, hospitalizations, and deaths in the United States — 2019–2020 influenza season. 2020. https://www.cdc.gov/flu/about/burden/2019-2020.html#:~:text=CDC%20estimates%20that%20the%20burden,flu%20deaths (Table 1). Accessed 7 July 2021.

22.

Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391:1285–300.PubMed

23.

Sellers SA, Hagan RS, Hayden FG, Fischer WA. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influenza Other Respi Viruses. 2017;11:372–93.

24.

Garten R, Blanton L, Elal AIA, et al. Update: influenza activity in the United States during the 2017–18 season and composition of the 2018–19 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2018;67:634–42.PubMedPubMedCentral

25.

Centers for Diseases Control and Prevention (CDC). Flu activity & surveillance. 2020. https://www.cdc.gov/flu/weekly/fluactivitysurv.htm. Accessed 7 July 2021.

26.

Schattner A. Acute cardiovascular events associated with influenza in hospitalized adults. Ann Intern Med. 2021;174:583.PubMed

27.

Ludwig A, Lucero-Obusan C, Schirmer P, Winston C, Holodniy M. Acute cardiac injury events ≤30 days after laboratory-confirmed influenza virus infection among U.S. veterans, 2010–2012. BMC Cardiovasc Disord. 2015;15:109.PubMedPubMedCentral

28.

Chang T-Y, Chao T-F, Liu C-J, Chen S-J, Chung F-P, Liao J-N, Tuan T-C, Chen T-J, Chen S-A. The association between influenza infection, vaccination, and atrial fibrillation: a nationwide case-control study. Hear Rhythm. 2016;13:1189–94.

29.

Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10:e0118369.PubMedPubMedCentral

30.

Schneider A, Panagiotakos D, Picciotto S, et al. Air temperature and inflammatory responses in myocardial infarction survivors. Epidemiology. 2008;19:391–400.PubMed

31.

Bhaskaran K, Hajat S, Haines A, Herrett E, Wilkinson P, Smeeth L. Short term effects of temperature on risk of myocardial infarction in England and Wales: time series regression analysis of the Myocardial Ischaemia National Audit Project (MINAP) registry. BMJ. 2010;341:c3823–c3823.PubMedPubMedCentral

32.

Warren-Gash C, Bhaskaran K, Hayward A, Leung GM, Lo S-V, Wong C-M, Ellis J, Pebody R, Smeeth L, Cowling BJ. Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong. J Infect Dis. 2011;203:1710–8.PubMedPubMedCentral

33.

Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J. 2018;51:1701794.PubMedPubMedCentral

34.

Blackburn R, Zhao H, Pebody R, Hayward A, Warren-Gash C. Laboratory-confirmed respiratory infections as predictors of hospital admission for myocardial infarction and stroke: time-series analysis of English data for 2004–2015. Clin Infect Dis. 2018;67:8–17.PubMedPubMedCentral

35.

Kytömaa S, Hegde S, Claggett B, Udell JA, Rosamond W, Temte J, Nichol K, Wright JD, Solomon SD, Vardeny O. Association of influenza-like illness activity with hospitalizations for heart failure. JAMA Cardiol. 2019;4:363.PubMedPubMedCentral

36.

Ohland J, Warren-Gash C, Blackburn R, Mølbak K, Valentiner-Branth P, Nielsen J, Emborg H-D. Acute myocardial infarctions and stroke triggered by laboratory-confirmed respiratory infections in Denmark, 2010 to 2016. Eurosurveillance. 2020. https://doi.org/10.2807/1560-7917.ES.2020.25.17.1900199.CrossRefPubMedPubMedCentral

37.

García‐Lledó A, Rodríguez‐Martín S, Tobías A, García‐de‐Santiago E, Ordobás‐Gavín M, Ansede‐Cascudo JC, Alonso‐Martín J, de Abajo FJ. Relationship between influenza, temperature, and type 1 myocardial infarction: An ecological time‐series study. J Am Heart Assoc. 2021;10:e019608.

38.

Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients. JAMA. 2013;310:1711.PubMed

39.

Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015. https://doi.org/10.1002/14651858.CD005050.pub3.CrossRefPubMedPubMedCentral

40.

Rodrigues BS, Alves M, Duarte GS, Costa J, Pinto FJ, Caldeira D. The impact of influenza vaccination in patients with cardiovascular disease: an overview of systematic reviews. Trends Cardiovasc Med. 2020. https://doi.org/10.1016/j.tcm.2020.06.003.CrossRefPubMed

41.

Yedlapati SH, Khan SU, Talluri S, et al. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc. 2021. https://doi.org/10.1161/JAHA.120.019636.CrossRefPubMedPubMedCentral

42.

Modin D, Jørgensen ME, Gislason G, Jensen JS, Køber L, Claggett B, Hegde SM, Solomon SD, Torp-Pedersen C, Biering-Sørensen T. Influenza vaccine in heart failure: cumulative number of vaccinations, frequency, timing, and survival: a Danish nationwide cohort study. Circulation. 2019. https://doi.org/10.1161/CIRCULATIONAHA.118.036788.CrossRefPubMed

43.

Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575–81.PubMed

44.

McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: β-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784.PubMed

45.

Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer. Circulation. 2017. https://doi.org/10.1161/CIR.0000000000000509.CrossRefPubMedPubMedCentral

46.

Behrouzi B, Udell JA. Influenza vaccine as part of a heart disease armamentarium in the new cardio-respiratory virus era. Trends Cardiovasc Med. 2020. https://doi.org/10.1016/j.tcm.2020.07.001.CrossRefPubMedPubMedCentral

47.

Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, Witkowski JM, Franceschi C. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol. 2018. https://doi.org/10.3389/fimmu.2017.01960.CrossRefPubMedPubMedCentral

48.

Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14:576–90.PubMed

49.

Vardeny O, Sweitzer NK, Detry MA, Moran JM, Johnson MR, Hayney MS. Decreased immune responses to influenza vaccination in patients with heart failure. J Card Fail. 2009;15:368–73.PubMed

50.

Wu NC, Zost SJ, Thompson AJ, Oyen D, Nycholat CM, McBride R, Paulson JC, Hensley SE, Wilson IA. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLOS Pathog. 2017;13:e1006682.PubMedPubMedCentral

51.

Paules CI, Sullivan SG, Subbarao K, Fauci AS. Chasing seasonal influenza — the need for a universal influenza vaccine. N Engl J Med. 2018;378:7–9.PubMed

52.

Zost SJ, Parkhouse K, Gumina ME, Kim K, Diaz Perez S, Wilson PC, Treanor JJ, Sant AJ, Cobey S, Hensley SE. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci. 2017;114:12578–83.PubMedPubMedCentral

53.

Nachbagauer R, Feser J, Naficy A, et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med. 2021;27:106–14.PubMed

54.

Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov. 2015;14:167–82.PubMed

55.

DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635–45.PubMed

56.

Van Ermen A, Hermanson MP, Moran JM, Sweitzer NK, Johnson MR, Vardeny O. Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study. Eur J Heart Fail. 2013;15:560–4.PubMedPubMedCentral

57.

DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, Greenberg DP. Prevention of serious events in adults 65 years of age or older: a comparison between high-dose and standard-dose inactivated influenza vaccines. Vaccine. 2015;33:4988–93.PubMed

58.

Vardeny O, Udell JA, Joseph J, et al. High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: rationale and design of the INVESTED trial. Am Heart J. 2018;202:97–103.PubMedPubMedCentral

59.

Bhatt AS, Vardeny O, Udell JA, Joseph J, Kim K, Solomon SD. Influenza vaccination: a ‘shot’ at INVESTing in cardiovascular health. Eur Heart J. 2021. https://doi.org/10.1093/eurheartj/ehab133.CrossRefPubMedPubMedCentral

60.

•• Vardeny O, Kim K, Udell JA, et al. Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease. JAMA. 2021;325:39 These are the recent results of the first large influenza vaccine cardiovascular outcome trial, INVESTED, in patients with high-risk CVD, including previous MI and HF hospitalizations.PubMed

61.

•• Hollingsworth R, Palmu A, Pepin S, Dupuy M, Shrestha A, Jokinen J, Syrjänen R, Nealon J, Samson S, De Bruijn I. Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: rationale and design of a real-world pragmatic randomized clinical trial. Am Heart J. 2021. https://doi.org/10.1016/j.ahj.2021.03.007This is the design of the newest large influenza vaccine cardiovascular outcome (registry-based) trial, conducted by the Finnish Institute for Health and Welfare, in patients aged 65 and up.CrossRefPubMed

62.

• Fröbert O, Götberg M, Angerås O, et al. Design and rationale for the influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial. Am Heart J. 2017;189:94–102 This is the design of the first registry-based, large influenza vaccine cardiovascular outcome trial in patients with acute coronary syndrome undergoing coronary angiography.PubMed

63.

• Loeb M, Dokainish H, Dans A, et al. Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): rationale and design. Am Heart J. 2019;212:36–44 This is the design of a large influenza vaccine cardiovascular outcome trial in patients with HF.PubMedPubMedCentral

64.

Grohskopf LA, Alyanak E, Broder KR, Blanton LH, Fry AM, Jernigan DB, Atmar RL. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices — United States, 2020–21 Influenza Season. MMWR Recomm Reports. 2020;69:1–24.

65.

Nylén G, Linde A, Kettis AA, Wik O, Stenmark S, Erntell M. Health personnel the key to high vaccination coverage against influenza. Lakartidningen. 109:8–9

66.

Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15:505–22.PubMedPubMedCentral

67.

Laurie KL, Rockman S. Which influenza viruses will emerge following the SARS‐CoV‐2 pandemic? Influenza Other Respi Viruses. 2021;15:573–576.

68.

Young B, Zhao X, Cook AR, Parry CM, Wilder-Smith A, I-Cheng MC. Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. Vaccine. 2017;35:212–21.PubMed

69.

Myhre PL, Grundvold I, Paulsen TH, Omland T, Schirmer H. Cardiovascular hospitalizations, influenza activity, and COVID-19 measures. Circulation. 2020;142:1302–4.PubMedPubMedCentral

70.

O’Halloran AC, Lu P, Williams WW, Bridges CB, Singleton JA. Influenza vaccination coverage among people with high-risk conditions in the U.S. Am J Prev Med. 2016;50:e15–26.PubMed

71.

Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices — United States, 2019–20 Influenza Season. MMWR Recomm Rep. 2019;68:1–21.PubMedPubMedCentral

72.

Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 Update. Circulation. 2006;113:2363–72.PubMed

73.

Grandhi GR, Mszar R, Vahidy F, Valero-Elizondo J, Blankstein R, Blaha MJ, Virani SS, Andrieni JD, Omer SB, Nasir K. Sociodemographic disparities in influenza vaccination among adults with atherosclerotic cardiovascular disease in the United States. JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.3978.CrossRefPubMedCentral

74.

Sperling LS, Albert MA, Koppaka R. Disparities in influenza vaccination—opportunity to extend cardiovascular prevention to millions of hearts. JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.3983.CrossRef

75.

WHO (World Health Organization). Ten threats to global health in 2019. 2019. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019. Accessed 7 July 2021.

76.

Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27:225–8.PubMed

77.

WHO (World Health Organization). Report of the SAGE working group on vaccine hesitancy. 2014. https://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf. Accessed 7 July 2021.

78.

Schattner A. Cardiovascular-targeted patient education and uptake of influenza vaccination in elderly patients. Patient Educ Couns. 2020;103:1052–4.PubMed

79.

Bhugra P, Grandhi GR, Mszar R, Satish P, Singh R, Blaha M, Blankstein R, Virani SS, Cainzos‐Achirica M, Nasir K. Determinants of influenza vaccine uptake in patients with cardiovascular disease and strategies for improvement. J Am Heart Assoc. 2021;10:e019671.

80.

Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021. https://doi.org/10.1038/s41586-021-03553-9.CrossRefPubMed

81.

Proal A, Marshall T. Myalgic encephalomyelitis/chronic fatigue syndrome in the era of the human microbiome: persistent pathogens drive chronic symptoms by interfering with host metabolism, gene expression, and immunity. Front Pediatr. 2018. https://doi.org/10.3389/fped.2018.00373.CrossRefPubMedPubMedCentral

82.

Magnus P, Gunnes N, Tveito K, Bakken IJ, Ghaderi S, Stoltenberg C, Hornig M, Lipkin WI, Trogstad L, Håberg SE. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. Vaccine. 2015;33:6173–7.PubMed

83.

Abbasi J. The search for a universal flu vaccine heats up. JAMA. 2019;322:1942.PubMed

84.

Eisenstein M. Towards a universal flu vaccine. Nature. 2019;573:S50–2.PubMed

Titel: Moving the Needle on Atherosclerotic Cardiovascular Disease and Heart Failure with Influenza Vaccination
verfasst von: Bahar Behrouzi
Jacob A. Udell
Publikationsdatum: 01.12.2021
Verlag: Springer US
Erschienen in: Current Atherosclerosis Reports / Ausgabe 12/2021
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-021-00973-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Anzeige

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen